{"id":94955,"date":"2020-12-14T05:00:00","date_gmt":"2020-12-14T05:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2778881"},"modified":"2020-12-14T05:00:00","modified_gmt":"2020-12-14T05:00:00","slug":"the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/","title":{"rendered":"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis"},"content":{"rendered":"<p><img decoding=\"async\" width=\"147\" height=\"147\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><em>Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise \/ larger production capacities of CMOs \/ CDMOs and achieve significant cost and time related advantages<\/em><\/p>\n<p><a href=\"https:\/\/www.rootsanalysis.com\/\"><strong>Roots Analysis<\/strong><\/a> is pleased to announce the publication of its recent study, titled, &nbsp;&ldquo;<a href=\"https:\/\/rootsanalysis.com\/reports\/view_document\/biopharma-contract-manufacturing-market-3rd-edition-2019-2030\/250.html\"><strong>Biopharma Contract Manufacturing Market (3<sup>rd<\/sup> Edition), 2019-2030<\/strong><\/a><strong>.<\/strong>&rdquo;&nbsp;<\/p>\n<p>The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:<\/p>\n<ul>\n<li>A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.<\/li>\n<li>Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.<\/li>\n<li>A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.<\/li>\n<li>A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.<\/li>\n<li>A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.<\/li>\n<li>A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug \/ therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.<\/li>\n<li>An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.<\/li>\n<li>A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.<\/li>\n<li>An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.<\/li>\n<li>An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.<\/li>\n<li>A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.<\/li>\n<li>A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.<\/li>\n<li>A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.<\/li>\n<li>A survey analysis featuring inputs solicited from various experts who are directly \/ indirectly involved in providing CMO services to medical device developers.<\/li>\n<li>A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)<\/li>\n<li>Commonly Outsourced Business Operations<\/li>\n<li>Active Pharmaceutical Ingredients (API)<\/li>\n<li>Finished Dosage Formulations (FDF)<\/li>\n<li>Types of Expression System<\/li>\n<li>Mammalian<\/li>\n<li>Microbial<\/li>\n<li>Others<\/li>\n<li>Company Size<\/li>\n<li>Small<\/li>\n<li>Mid-Sized<\/li>\n<li>Large and Very Large<\/li>\n<li>Scale of Operation<\/li>\n<li>Preclinical<\/li>\n<li>Clinical<\/li>\n<li>Commercial<\/li>\n<li>Key Geographical Region&nbsp;<\/li>\n<li>North America<\/li>\n<li>Europe<\/li>\n<li>Asia-Pacific<\/li>\n<li>Rest of the World&nbsp;<\/li>\n<\/ul>\n<p>The report also features detailed transcripts of discussions held with the following experts:<\/p>\n<ul>\n<li>Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)<\/li>\n<li>Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie<\/li>\n<li>Christian Bailly, Director of CDMO, Pierre Fabre<\/li>\n<li>Claire Otjes, Assistant Marketing Manager, Batavia Biosciences<\/li>\n<li>David C Cunningham, Director Corporate Development, Goodwin Biotechnology<\/li>\n<li>Dietmar Katinger, Chief Executive Officer, Polymun Scientific<\/li>\n<li>Denis Angioletti, Chief Commercial Officer, Cerbios-Pharma<\/li>\n<li>Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences<\/li>\n<li>Kevin Daley, Director Pharmaceuticals, Novasep<\/li>\n<li>Mark Wright, Site Head, Grangemouth, Piramal Healthcare<\/li>\n<li>Nicolas Grandchamp, R&amp;D Leader, GEG Tech<\/li>\n<li>Raquel Fortunato, Chief Executive Officer, GenIbet Biopharmaceuticals<\/li>\n<li>Sebastian Schuck, Head of Business Development, Wacker Biotech<\/li>\n<li>Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies<\/li>\n<li>Tatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactory<\/li>\n<li>Tim Oldham, Chief Executive Officer, Cell Therapies<\/li>\n<\/ul>\n<p>Key companies covered in the <a href=\"https:\/\/rootsanalysis.com\/reports\/view_document\/biopharma-contract-manufacturing-market-3rd-edition-2019-2030\/250.html\">report<\/a><\/p>\n<ul>\n<li>3P Biopharmaceuticals<\/li>\n<li>Abzena<\/li>\n<li>Albany Molecular Research<\/li>\n<li>BioVectra<\/li>\n<li>BioXcellence (Boehringer Ingelheim)<\/li>\n<li>Celonic<\/li>\n<li>Charles River Laboratories<\/li>\n<li>ChemPartner<\/li>\n<li>Cobra Biologics<\/li>\n<li>CordenPharma<\/li>\n<li>Cytovance Biologics<\/li>\n<li>GE Healthcare<\/li>\n<li>Goodwin Biotechnology<\/li>\n<li>Grand River Aseptic Manufacturing<\/li>\n<li>IDT Biologika<\/li>\n<li>KBI BioPharma<\/li>\n<li>Kemwell Biopharma<\/li>\n<li>LFB Biomanufacturing<\/li>\n<li>Meridian Life Science<\/li>\n<li>Patheon<\/li>\n<li>Pfizer CentreOne<\/li>\n<li>PX&#8217;Therapeutics<\/li>\n<li>Samsung BioLogics<\/li>\n<li>Sanofi, CEPiA<\/li>\n<li>Thermo Fisher Scientific<\/li>\n<li>Vetter Pharma International<\/li>\n<\/ul>\n<p>For more information please click on the following link:<\/p>\n<p><a href=\"https:\/\/rootsanalysis.com\/reports\/view_document\/biopharma-contract-manufacturing-market-3rd-edition-2019-2030\/250.html\"><strong>Biopharma Contract Manufacturing Market (3<sup>rd<\/sup> Edition), 2019-2030<\/strong><\/a><\/p>\n<p><strong>Other Recent Offerings<\/strong><\/p>\n<ol>\n<li><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/cell-therapy-manufacturing\/285.html\">Cell Therapy Manufacturing Market (3<sup>rd<\/sup> Edition), 2019-2030<\/a><\/li>\n<li><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/antibody-cmo-market\/295.html\">Antibody Contract Manufacturing Market, 2020-2030<\/a><\/li>\n<li><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/china-biopharmaceutical-contract-manufacturing\/313.html\">China Biopharmaceutical Contract Manufacturing Market, 2020-2030<\/a><\/li>\n<li><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/peptide-therapeutics-manufacturing\/305.html\">Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030<\/a><\/li>\n<\/ol>\n<p><strong>About Roots Analysis<\/strong><\/p>\n<p>Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you&rsquo;d like help with your growing business needs, get in touch at info@rootsanalysis.com<\/p>\n<p class=\"tags\">Tags: <a href=\"https:\/\/icrowdnewswire.com\/tag\/pharma-reports\/\" rel=\"tag\">Pharma Reports<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/research\/\" rel=\"tag\">Research<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/capacity\/\" rel=\"tag\">CAPACITY<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/biotech\/\" rel=\"tag\">biotech<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/market\/\" rel=\"tag\">market<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/report\/\" rel=\"tag\">report<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/segment\/\" rel=\"tag\">segment<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/market-reports\/\" rel=\"tag\">market reports<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/373164\/\" rel=\"tag\">\u00a0<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/biopharma\/\" rel=\"tag\">Biopharma<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/contract-manufacturing\/\" rel=\"tag\">contract manufacturing<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/roots-analysis\/\" rel=\"tag\">Roots Analysis<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/tag\/biopharmaceutical-cmo\/\" rel=\"tag\">Biopharmaceutical CMO<\/a><\/p>\n<div><strong>See Campaign: <\/strong><a href=\"https:\/\/www.rootsanalysis.com\/reports\/view_document\/biopharma-contract-manufacturing-market-3rd-edit\" target=\"_blank\">https:\/\/www.rootsanalysis.com\/reports\/view_document\/biopharma-contract-manufacturing-market-3rd-edit<\/a><br \/><b>Contact Information:<\/b><br \/>Gaurav Chaudhary<br \/>\ngaurav.chaudhary@rootsanalysis.com<br \/>\nRoots Analysis<br \/>\nA430, 4th Floor,<br \/>\nBestech Business Towers, Sector 66, Mohali, India<br \/>\nsales@rootsanalysis.com<br \/>\n+1 (415) 800 3415<br \/>\n+44 (122) 391 1091<br \/>\nWeb: https:\/\/www.rootsanalysis.com\/<br \/>\nLinkedIn: https:\/\/in.linkedin.com\/company\/roots-analysis<br \/>\nTwitter: https:\/\/twitter.com\/RootsAnalysis<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/ips\/\" rel=\"category tag\">IPS<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/reportedtimes\/\" rel=\"category tag\">Reportedtimes<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/extended-distribution\/\" rel=\"category tag\">Extended Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/wire\/\" rel=\"category tag\">Wire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/icn-internal-distribution\/\" rel=\"category tag\">iCN Internal Distribution<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/research-newswire\/\" rel=\"category tag\">Research Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Gaurav Chaudhary<br \/>\ngaurav.chaudhary@rootsanalysis.com<br \/>\nRoots Analysis<br \/>\nA430, 4th Floor,<br \/>\nBestech Business Towers, Sector 66, Mohali, India<br \/>\nsales@rootsanalysis.com<br \/>\n+1 (415) 800 3415<br \/>\n+44 (122) 391 1091<br \/>\nWeb: https:\/\/www.rootsanalysis.com\/<br \/>\nLinkedIn: https:\/\/in.linkedin.com\/company\/roots-analysis<br \/>\nTwitter: https:\/\/twitter.com\/RootsAnalysis<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p><img decoding=\"async\" width=\"147\" height=\"147\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png\" alt=\"\" loading=\"lazy\" link_thumbnail=\"\">Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise \/ larger production capacities of CMOs \/ CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, &nbsp;&ldquo;Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.&rdquo;&nbsp; The report features an &hellip; <a href=\"https:\/\/icrowdnewswire.com\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\">Continue reading <span>The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis<\/span><\/a> <a href=\"https:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":248,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,5,67,57,64,4,54],"tags":[],"class_list":["post-94955","post","type-post","status-publish","format-standard","hentry","category-english","category-extended-distribution","category-icn-internal-distribution","category-ips","category-reportedtimes","category-research-newswire","category-wire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis - Business\" \/>\n<meta property=\"og:description\" content=\"Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise \/ larger production capacities of CMOs \/ CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, &nbsp;&ldquo;Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.&rdquo;&nbsp; The report features an &hellip; Continue reading The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-14T05:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png\" \/>\n<meta name=\"author\" content=\"roots.analysis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"roots.analysis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\",\"name\":\"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png\",\"datePublished\":\"2020-12-14T05:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/99a172f95a70a5b8135ddad53fdf2451\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/99a172f95a70a5b8135ddad53fdf2451\",\"name\":\"roots.analysis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f98002c4347627ab3e788c29a8a843cd26aa1504a8cd35e524fddd188793bee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f98002c4347627ab3e788c29a8a843cd26aa1504a8cd35e524fddd188793bee?s=96&d=mm&r=g\",\"caption\":\"roots.analysis\"},\"sameAs\":[\"https:\/\/icrowdnewswire.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/roots-analysis\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/","og_locale":"en_US","og_type":"article","og_title":"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis - Business","og_description":"Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise \/ larger production capacities of CMOs \/ CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, &nbsp;&ldquo;Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.&rdquo;&nbsp; The report features an &hellip; Continue reading The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/","og_site_name":"Business","article_published_time":"2020-12-14T05:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png","type":"","width":"","height":""}],"author":"roots.analysis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"roots.analysis","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/","url":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/","name":"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png","datePublished":"2020-12-14T05:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/99a172f95a70a5b8135ddad53fdf2451"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2020\/12\/4671-1607926549.png"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2020\/12\/14\/the-biopharmaceutical-contract-manufacturing-market-is-estimated-to-be-worth-usd-13-9-billion-in-2030-predicts-roots-analysis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"The biopharmaceutical contract manufacturing market is estimated to be worth USD 13.9 billion in 2030, predicts Roots Analysis"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/99a172f95a70a5b8135ddad53fdf2451","name":"roots.analysis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7f98002c4347627ab3e788c29a8a843cd26aa1504a8cd35e524fddd188793bee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f98002c4347627ab3e788c29a8a843cd26aa1504a8cd35e524fddd188793bee?s=96&d=mm&r=g","caption":"roots.analysis"},"sameAs":["https:\/\/icrowdnewswire.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/roots-analysis\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/94955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/248"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=94955"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/94955\/revisions"}],"predecessor-version":[{"id":94956,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/94955\/revisions\/94956"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=94955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=94955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=94955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}